• Global leader in testing solutions across diversified and high-growth end markets
• Strategically positioned to capture industry megatrends in regulation, energy transition, and digitalisation
• Track record of shareholder value creation through revenue growth, EPS growth, and shareholder returns

ALS is a global leader in testing solutions, exposed to a range of diversified and high-growth end markets. The company is strategically positioned to capture multi-decade industry megatrends across increasing regulation and outsourcing, energy transition and digitalisation. ALS has a track record of shareholder value creation, consistently delivering revenue growth, EPS growth and shareholder returns. ALS has a strong pipeline of capital opportunities that align with its Value Creation Framework, including a A$230 million organic investment in the laboratory network to upgrade four major hub laboratories that are approaching capacity, to support ongoing organic growth in minerals and environmental business units. The company is also executing on a pipeline of value accretive M&A, with a focus on the minerals and environmental segments.ALS is launching a fully underwritten A$350 million institutional placement, representing 4.3% of existing shares on issue, at a 5.3% discount to the last traded price. Proceeds will be used to fund the organic investment in the laboratory network, with excess funds used to maintain balance sheet flexibility and support future growth initiatives. Eligible existing shareholders will also be offered the opportunity to acquire up to A$30,000 of new shares via a non-underwritten share purchase plan.The deployment of the A$230 million investment in the laboratory network is expected to result in mid single digit pro forma FY25 EPS accretion, with further EPS accretion expected from the deployment of remaining proceeds in future growth initiatives that meet ALS' return hurdles. The equity raise will also provide ALS with a pro forma undrawn bank capacity of A$677 million and a pro forma leverage ratio of 1.7x immediately after the equity raise, or A$447 million and 2.1x post the A$230 million investment in the laboratory network.

The deployment of the A$230 million investment in the laboratory network is expected to result in mid single digit pro forma FY25 EPS accretion, with further EPS accretion expected from the deployment of remaining proceeds in future growth initiatives that meet ALS' return hurdles.